Proportion of the target population who received the final dose of in Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)
Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand): Proportion of the target population who received the final dose of was 44.0% in 2024. ▲ Rising
Proportion of the target population who received the final dose of in Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand), 2010–2024
Source: United Nations Statistics Division, SDG Global Database.
Analysis
The most recent figure for proportion of the target population who received the final dose of in Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand) is 44.0%, measured in 2024. That is the highest value across all 15 years on record.
Compared with earlier readings it is up 2.3% on the previous year and up 57.1% over ten years.
Over the whole period, proportion of the target population who received the final dose of in Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand) peaked at 44.0% in 2024 and was at its lowest, 19.0%, in 2010.
That places Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand) 17th out of 35 groups with data for 2024, putting it in the middle of the range.
The long-run direction has been consistently rising across the 15 years of available data.
Proportion of the target population who received the final dose of in Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand), year by year
| Year | Value | Change |
|---|---|---|
| 2010 | 19.0% | — |
| 2011 | 23.0% | +21.1% |
| 2012 | 24.0% | +4.3% |
| 2013 | 29.0% | +20.8% |
| 2014 | 28.0% | -3.4% |
| 2015 | 30.0% | +7.1% |
| 2016 | 33.0% | +10.0% |
| 2017 | 36.0% | +9.1% |
| 2018 | 35.0% | -2.8% |
| 2019 | 40.0% | +14.3% |
| 2020 | 38.0% | -5.0% |
| 2021 | 40.0% | +5.3% |
| 2022 | 42.0% | +5.0% |
| 2023 | 43.0% | +2.4% |
| 2024 | 44.0% | +2.3% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 29.7% | 19.0% | 40.0% | 10 |
| 2020s | 41.4% | 38.0% | 44.0% | 5 |
Countries ranked near Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)
More infrastructure data for Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)
- Proportion of the target population who received 3 doses of 94.0% (2024)
- Developing countries’ and least developed countries’ share of global 55.7% (2024)
- Developing countries’ and least developed countries’ share of global 51.7% (2024)
- Developing countries’ and least developed countries’ share of global 64.2% (2024)
- Developing countries’ and least developed countries’ share of global 68.5% (2024)
- Total official flows for infrastructure, by recipient countries 6,728 (2024)
- Proportion of the target population who received 91.0% (2024)
- Container port traffic, maritime transport 221.66 million (2024)
- Proportion of the target population who received a 3rd dose of 84.0% (2024)
- Proportion of tariff lines applied to imports with zero-tariff 56.8% (2024)
Frequently asked questions
- What is proportion of the target population who received the final dose of in Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)?
- Proportion of the target population who received the final dose of in Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand) was 44.0% in 2024, according to United Nations Statistics Division, SDG Global Database.
- What is the highest proportion of the target population who received the final dose of recorded in Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)?
- The highest recorded value was 44.0% in 2024.
- What is the lowest proportion of the target population who received the final dose of recorded in Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)?
- The lowest recorded value was 19.0% in 2010.
- How does Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand) rank for proportion of the target population who received the final dose of?
- Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand) ranks 17th out of 35 groups with data for 2024.
- Is proportion of the target population who received the final dose of rising or falling in Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)?
- Over the last ten years it is up 57.1%. The long-run trend across the full record is rising.
- Where does this Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand) data come from?
- The figures come from United Nations Statistics Division, SDG Global Database, published as part of Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 15 observations, free to reuse under UN SDG Global Database (open, attribution requested).